Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.57 |
| ▸ | APP | P05067 | 4/20 | 0.43 |
| ▸ | ABL1 | P00519 | 2/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.43 |
| ▸ | BCR | P11274 | 2/20 | 0.43 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 7/20 | 0.38 |
| ▸ | CA9 | Q16790 | 7/20 | 0.38 |
| ▸ | CA2 | P00918 | 6/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 6/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | CA5A | P35218 | 5/20 | 0.38 |
| ▸ | CA1 | P00915 | 5/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 4/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.38 |
| ▸ | CA3 | P07451 | 4/20 | 0.38 |
| ▸ | CA4 | P22748 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL673158 | 0.88 | APP (0.61) | BACE1APPABL1ABCB1BCR | |
| SCHEMBL4267409 | 0.84 | APP (0.60) | BACE1APPABL1ABCB1BCR | |
| SCHEMBL12535886 | 0.84 | ALDH1A1 (0.57) | BACE1APPABL1ABCB1BCR | |
| SCHEMBL19026498 | 0.82 | APP (0.57) | APPCA12CA9CA2CA1 | |
| SCHEMBL4267440 | 0.80 | ALOX5 (0.43) | BACE1APPABL1ABCB1BCR | |
| SCHEMBL4277452 | 0.80 | PTGS1 (0.47) | BACE1APPCA12CA9CA2 | |
| SCHEMBL4267390 | 0.80 | ACHE (0.52) | BACE1APPACHECA12CA9 | |
| SCHEMBL4264799 | 0.80 | APP (0.46) | BACE1APPCA12CA9CA2 | |
| SCHEMBL22708286 | 0.78 | BACE1 (0.40) | BACE1APPABL1ABCB1BCR | |
| SCHEMBL20211704 | 0.78 | APP (0.60) | APPCA12CA9CA2CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11786481-B2 | Formulation and process for modulating wound healing | BioMendics, LLC (US) | 2023-10-17 | — | — | US | claimed |
| US-20210228501-A1 | Formulation and Process for Modulating Wound Healing | BioMendics, LLC (US) | 2021-07-29 | — | — | US | claimed |
| US-10426742-B2 | Formulation and process for modulating wound healing | BioMendics, LLC (US) | 2019-10-01 | — | — | US | claimed |
| US-20190022029-A1 | Formulation and Process for Modulating Wound Healing | BioMendics, LLC (US) | 2019-01-24 | — | — | US | claimed |
| EP-3280402-A2 | FORMULATION AND PROCESS FOR MODULATING WOUND HEALING | Biomendics LLC (US) | 2018-02-14 | — | — | EP | claimed |
| WO-2016164531-A2 | FORMULATION AND PROCESS FOR MODULATING WOUND HEALING | BioMendics, LLC (US) | 2016-10-13 | — | — | WO | claimed |
| US-20160296477-A1 | Formulation and Process for Modulating Wound Healing | BioMendics, LLC (US) | 2016-10-13 | — | — | US | claimed |
| US-8680142-B2 | Ascorbate, vitamin K3 and hydroxytolans in the treatment of cancer | KENT STATE UNIVERSITY (US) | 2014-03-25 | — | — | US | claimed |
| EP-3280402-B1 | TOLAN COMPOUNDS FOR PROMOTING WOUND HEALING | BIOMENDICS LLC (US) | 2024-06-05 | — | — | EP | disclosed |
| US-11786481-B2 | Formulation and process for modulating wound healing | BioMendics, LLC (US) | 2023-10-17 | — | — | US | disclosed |
| US-11786481-B2 | Formulation and process for modulating wound healing | BioMendics, LLC (US) | 2023-10-17 | — | — | US | disclosed |
| US-11786481-B2 | Formulation and process for modulating wound healing | BioMendics, LLC (US) | 2023-10-17 | — | — | US | disclosed |
| US-20220296538-A1 | Substituted Tolans for the Modulation of Microbial Colonization | BioMendics, LLC (US) | 2022-09-22 | — | — | US | disclosed |
| US-11351126-B2 | Substituted tolans for the modulation of microbial colonization | BioMendics, LLC (US) | 2022-06-07 | — | — | US | disclosed |
| WO-2009126700-A1 | HYDROXYLATED TOLANS AND RELATED COMPOUNDS AS COSMETICS OR THERAPEUTICS FOR SKIN CONDITIONS | KENT STATE UNIVERSITY (US) | 2009-10-15 | — | — | WO | disclosed |
| WO-2008157745-A1 | ASCORBATE, VITAMIN K3 AND HYDROXYTOLANS IN THE TREATMENT OF CANCER | KENT STATE UNIVERSITY (US) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008157787-A2 | HYDROXYLATED TOLANS AND RELATED COMPOUNDS IN THE TREATMENT OF CANCER | KENT STATE UNIVERSITY (US) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008157787-A2 | HYDROXYLATED TOLANS AND RELATED COMPOUNDS IN THE TREATMENT OF CANCER | KENT STATE UNIVERSITY (US) | 2008-12-24 | — | — | WO | disclosed |
| US-7094809-B2 | Topical administration of dihydroxytoluene to block viral replication | NORTHEASTERN OHIO UNIVERSITIES COLLEGE OF MEDICINE (US) | 2006-08-22 | — | — | US | disclosed |
| US-20030203974-A1 | Methods for treating subjects infected with herpes virus or Neisseria gonorrheae | DOCHERTY JOHN (US) | 2003-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11786481-B2 | Formulation and process for modulating wound healing | SQSTM1, ATG7, TFEB | BACE1 4779/4885APP 4010/4885ABL1 2543/4885 |
| US-20160296477-A1 | Formulation and Process for Modulating Wound Healing | SQSTM1, ATG7, TFEB | BACE1 4769/4885APP 4260/4885ABL1 2939/4885 |
| US-20210228501-A1 | Formulation and Process for Modulating Wound Healing | ATG7, SQSTM1, ATF4 | BACE1 4804/4885APP 3850/4885ABL1 2536/4885 |
| US-10426742-B2 | Formulation and process for modulating wound healing | SQSTM1, ATG7, TFEB | BACE1 4779/4885APP 4010/4885ABL1 2543/4885 |
| US-20190022029-A1 | Formulation and Process for Modulating Wound Healing | SQSTM1, ATG7, TFEB | BACE1 4779/4885APP 4010/4885ABL1 2543/4885 |
| US-11351126-B2 | Substituted tolans for the modulation of microbial colonization | LMAN1, DPM1, DSTN | BACE1 3044/4885APP 3466/4885ABL1 1044/4885 |
| US-20220296538-A1 | Substituted Tolans for the Modulation of Microbial Colonization | LMAN1, DPM1, DSTN | BACE1 3044/4885APP 3466/4885ABL1 1044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.